Treatment of fibrosis using FXR ligands
US-9498484-B2 · Nov 22, 2016 · US
Treatment of fibrosis using FXR ligands
US10987362B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10987362-B2 |
| Application number | US-201816228944-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 21, 2018 |
| Priority date | Mar 12, 2004 |
| Publication date | Apr 27, 2021 |
| Grant date | Apr 27, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating non-alcoholic steatohepatitis in a subject not suffering from a cholestatic condition, the method comprising the step of administering to the subject an effective amount of tauro-6-ethyl-chenodeoxycholic acid (tauro-6ECDCA). 2. The method of claim 1 , wherein tauro-6ECDCA is administered at a daily dose of 5-500 mg orally. 3. The method of claim 1 , wherein the cholestatic condition is defined as having abnormally elevated serum levels of alkaline phosphatase, γ-glutamyl transpeptidase (GGT), and 5′ nucleotidase. 4. The method of claim 3 , wherein the cholestatic condition is further defined as presenting with at least one clinical symptom. 5. The method of claim 4 , wherein the symptom is itching (pruritus).
Assignees
Inventors
Classifications
Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title
- A61P1/16Primary
for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title
- A61K31/575Primary
substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10987362B2 cover?
- The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective a…
- Who is the assignee on this patent?
- Intercept Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification A61P1/16. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).